Abstract

Patients with asthma often experience sleep disturbances, which can be associated with poor asthma control. This post hoc analysis used a composite criteria based on validated patient-reported outcomes to identify patients with HSD. Efficacy of dupilumab vs placebo in improving sleep quality and other clinical/patient-reported outcomes in patients with uncontrolled, moderate-to-severe asthma with elevated type 2 biomarkers, 5-item asthma control questionnaire (ACQ-5) scores ≥2.5, and high sleep disturbance (HSD), at baseline of phase 3 QUEST (NCT02414854) is reported.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call